Vectura Group plc Vectura appoints Chief Commercial Officer
09 Marzo 2020 - 8:00AM
RNS Non-Regulatory
TIDMVEC
Vectura Group plc
09 March 2020
Vectura appoints Mark Bridgewater as Chief Commercial
Officer
New role will further strengthen leadership team to drive
business development and growth
Chippenham, UK - 09 March 2020 : Vectura Group plc (LSE: VEC)
("Vectura", "the Company" or "the Group") today announced a key
leadership appointment to drive business development and growth as
the Company continues with its strategy to become a leading
inhalation specialist in the pharmaceutical services space.
Mark Bridgewater has been appointed as Chief Commercial Officer,
a newly-created role focussed on helping the Company to transform
into a successful contract development and manufacturing
organisation (CDMO). In his new position, Mr Bridgewater will
implement strong sales processes in order to secure new business,
as well as building out a world-class commercial team and driving
Vectura's brand market presence.
Will Downie, CEO of Vectura, said: "I am thrilled to have Mark
join Vectura, where he will play a pivotal role in driving the
future growth of the organisation. He comes to the Company with an
impressive track record of delivering sustained growth and market
success in each of his previous roles. His versatile leadership
skills and growth mindset will help accelerate the transformation
of the company into a true leader in the outsourcing space."
Mr Bridgewater added: "I am delighted to be joining Vectura at
such an exciting time, as the Company pivots to become a leader in
the CDMO market. I look forward to working with my new colleagues
to drive value for customers, employees and shareholders."
Mr Bridgewater has more than 20 years of experience in medical
device and pharmaceutical services. Prior to joining Vectura, he
was VP Business Development and Account Management for Europe and
Asia at Flex, a global design, engineering and manufacturing
organisation. Previously, he was VP Global Business Development,
Advanced Delivery Technologies at Catalent, and earlier in his
career worked as Head of Global Manufacturing Services at Wockhardt
and Senior Business Manager, Italy, for Patheon.
- Ends-
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / David Daley +44 (0)20 3709 5700
About Vectura
Vectura is a provider of innovative inhaled drug delivery
services that enable partners to bring their medicines to patients.
With differentiated proprietary technology and pharmaceutical
development expertise, Vectura is one of the few companies globally
with the device, formulation and development capabilities to
deliver a broad range of complex inhaled therapies.
Vectura has ten key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
For further information, please visit Vectura's website at
www.vectura.com
Forward-looking statements
This press release contains forward-looking statements,
including statements about the commercialisation of products.
Various risks may cause Vectura's actual results to differ
materially from those expressed or implied by the forward looking
statements, including: commercial limitations imposed by patents
owned or controlled by third parties; dependence upon strategic
alliance partners to develop and commercialise products and
services; difficulties or delays in obtaining regulatory approvals
to market products and services resulting from development efforts;
the requirement for substantial funding to conduct research and
development and to expand commercialisation activities; and product
initiatives by competitors. As a result of these factors,
prospective investors are cautioned not to rely on any
forward-looking statements. We disclaim any intention or obligation
to update or revise any forward looking statements, whether as a
result of new information, future events or otherwise.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAKDKEFLEEFA
(END) Dow Jones Newswires
March 09, 2020 03:00 ET (07:00 GMT)
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Apr 2023 a Apr 2024